Table 1. Outcome According to Clinical... | American Society of Hematology

Table 1.

Outcome According to Clinical Features: 100 Patients With FLCL

Feature	No. of Patients	CR (%)	5-yr FFS (%)	5-yr Survival (%)	Median Survival (mo)
All patients	100	85	67	72	141
Age
<60	54	91	65	85	120
≥60	46	78	69	57^*	64^*
Ann Arbor Stage
I	26	96	85	90	NR
II	22	91	86	73	77
III	29	93	62	71	135
IV	23	57^*	37^*	51^*	60^*
No. E sites
0, 1	93	87	69	78	124
≥2	7	57	43	29^†	27^†
LDH
Low	70	89	73	82	120
High	30	77	53	50^†	43^†
Marrow
Negative	82	94	77	80	141
Positive	18	44^†	19^†	41^†	52^†
β2M^‡
<3	70	91	77	76	113
≥3	10	50^*	54^*	12^†	13^†
IPI
Low	59	92	75	85	160
Low-Int	26	81	64	69	108
High-Int	13	77	38	28	35
High	2	0^†	0^†	0^†	12^†
Tumor score^‡
<3	67	91	81	77	117
≥3	13	66^*	44^*	26^†	28^†

Feature	No. of Patients	CR (%)	5-yr FFS (%)	5-yr Survival (%)	Median Survival (mo)
All patients	100	85	67	72	141
Age
<60	54	91	65	85	120
≥60	46	78	69	57^*	64^*
Ann Arbor Stage
I	26	96	85	90	NR
II	22	91	86	73	77
III	29	93	62	71	135
IV	23	57^*	37^*	51^*	60^*
No. E sites
0, 1	93	87	69	78	124
≥2	7	57	43	29^†	27^†
LDH
Low	70	89	73	82	120
High	30	77	53	50^†	43^†
Marrow
Negative	82	94	77	80	141
Positive	18	44^†	19^†	41^†	52^†
β2M^‡
<3	70	91	77	76	113
≥3	10	50^*	54^*	12^†	13^†
IPI
Low	59	92	75	85	160
Low-Int	26	81	64	69	108
High-Int	13	77	38	28	35
High	2	0^†	0^†	0^†	12^†
Tumor score^‡
<3	67	91	81	77	117
≥3	13	66^*	44^*	26^†	28^†

Statistically significant adverse features (P < .05).

Statistically significant adverse features (P < .01).

β2M data, and therefore Tumor Score assignment, unavailable for 20 patients.